Navigation Links
A Fresh Alternative to Painful Chemotherapy Developed in UK

Chemotherapy is a standard regimen in most cancer treatments. Since it is a very painful process, continuous attempts are made to replace it with something more comfortable for the patient.

Now researchers say that LHRH agonists like the drug Zoladex switch off the ovary and stop the production of a female hormone that encourages some tumours to grow.

An agonist achieves a normal action, often mimicking the action of a naturally occurring substance.

Luteinizing hormone-releasing hormone is a naturally occurring hormone that controls sex hormones in both men and women. Thus, an LHRH agonist serves in a manner similar to LHRH to control the same sex hormones.

Four London centres found that even when used alone, the chemical worked as well as conventional chemotherapy in some cases, the Lancet journal said.

Breast cancer charities say that younger women might benefit the most.

Many types of breast cancer are sensitive to hormones produced naturally by a woman, including the sex hormone oestrogen, and can grow faster if a woman is producing them. The London researchers, from the Cancer Research UK Centre for Epidemiology, the Wolfson Institute for Preventive Medicine, and Queen Mary's School of Medicine and Dentistry, combined the results of 16 other research projects into LHRH agonists and breast cancer.

When all the different results are added together, the overall findings offer a more reliable indicator as to how well the treatment works.

They found that pre-menopausal women given LHRH agonists did as well as those given standard chemotherapy.

When the two treatments were given together, the women did even better - with cancer 13% less likely to come back.

As expected, LHRH agonists were effective only where a tumour was proven to be sensitive to oestrogen.

The study authors said that the results proved th
'"/>




Page: 1 2

Related medicine news :

1. Fresh approach to TB treatment
2. Fresh warnings to doctors regarding abortion pill
3. Fresh Cases of Bird-Flu Prepares the Ground for More Chicken Martyrs
4. Fresh Bird Flu Cases Spotted In Southern Russia
5. Pakistan Scared By Fresh Bird Flu Case
6. Fresh Polio Cases Reported In Uttar Pradesh
7. Nothing Can Equate Fresh Vegetables and Fruits
8. Fresh Outbreak Of Bird Flu In Nigeria
9. Foreign Fresher Students Offered Scholarship By Fudan
10. Fresh bird flu vaccines made in China
11. Freshness Dating? Researchers Express Doubts
Post Your Comments:
(Date:12/2/2008)...tCall/ -- Quest Diagnostics Incorporated (NYSE: ...testing, information and services, announced that ...thcare Conference in New York City today, December...cheduled to begin at 4:00 p.m. Eastern Time. , ...affirm its 2008 guidance for revenue growth of gre...
(Date:12/2/2008)...er with aprotinin, a drug commonly used to control...y, compared with lysine analogues, according to a ...9 to be published in the January 20th issue of C...dvisory panel will meet to decide on aprotinin use...the meeting. , The study, a systematic review o...
(Date:12/2/2008)...rstCall/ - NUCRYST Pharmaceuticals Corp., a develo...t infection and inflammation, announced today that...rity shareholder, The Westaim Corporation ("Westai...areholders to consider a return of capital of US$0...s to a return of capital of approximately US$15 mi...
(Date:12/2/2008)...e Efficacy of Commercially Available Hypomethylati... Eisai Corporation of North Americ...rst clinical trial evaluating the activity of Daco...za(R) (azacitidine) in adult patients with interme...ic syndromes (MDS), a potentially life-threatening...
Breaking Medicine News(10 mins):Health News:Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 3Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3
... of Public Health have reported that over the coun...eneficial as they can lower the risk of Parkinson’... took daily one ibuprofen tablet, men and women, f...eople seemed to have a 38% less chance of having P...
... increased calcium intake by drinking milk or othe...of Parkinson’s disease. Parkinson’s disease is a d...s are muscle tremors, muscle rigidity, decreased m...low voluntary movements, and a mask-like facial ex...
... out how to elevate the functional limitations of ...e researchers of Feinberg School of Medicine, US ...and old with arthritis. Functions, which were chec...ng to daily living and specialized activities of d...
...ncy is associated with dental problems. But are th...trong enough to affect the babies’ birth weight or...ew York University College of Dentistry, US, say t...a affect the pregnancy by causing pre-term deliver...
Other Medicine News:
(Date:11/25/2008)...ss Survival of Patients Receiving Litx versus Stan...ular Carcinoma , , BELLEVUE, Wash., Nov. 25...O) today announced the completion of enrollment in... Therapy(TM) (Litx(TM)) as a treatment for unresec...s hepatoma or primary liver cancer. , , The...
(Date:11/24/2008)...ewswire/ -- Takeda Pharmaceutical Company Limited ...earch & Development Center, Inc., U.S., announ... the U.S. Food and Drug Administration (FDA) recom...eatment of hyperuricemia in patients with gout. Th...ne panel member abstaining. The vote followed pres...
(Date:11/24/2008).../ -- Leaders of Schering-Plough Corporation (NYSE:... the company,s research pipeline, highlighting a r...entities in clinical trials or under regulatory re...search and development is adding strength and brea...mation," said Fred Hassan, chairman and CEO. "Our...
(Date:11/24/2008)... long-term commitment to hepatitis research , ...ll/ -- Schering-Plough Corporation (NYSE: SGP ) ...s lead investigational oral hepatitis C protease i...company believes boceprevir has the potential to b...bitor for treating chronic hepatitis C. The compa...
Breaking Medicine Technology:Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 1Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 2Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 3Using DNA scientists hunt for the roots of the modern potato 2050 1Using DNA scientists hunt for the roots of the modern potato 2050 2American Red Cross Launches 2008 National Public Service Advertising Campaign 10429 1American Red Cross Launches 2008 National Public Service Advertising Campaign 10429 2Flextronics Announces Third Quarter Results 10427 1Flextronics Announces Third Quarter Results 10427 2Flextronics Announces Third Quarter Results 10427 3Flextronics Announces Third Quarter Results 10427 4Flextronics Announces Third Quarter Results 10427 5Flextronics Announces Third Quarter Results 10427 6Flextronics Announces Third Quarter Results 10427 7Flextronics Announces Third Quarter Results 10427 8Flextronics Announces Third Quarter Results 10427 9Flextronics Announces Third Quarter Results 10427 10Flextronics Announces Third Quarter Results 10427 11Flextronics Announces Third Quarter Results 10427 12Flextronics Announces Third Quarter Results 10427 13Flextronics Announces Third Quarter Results 10427 14Flextronics Announces Third Quarter Results 10427 15Flextronics Announces Third Quarter Results 10427 16Flextronics Announces Third Quarter Results 10427 17Flextronics Announces Third Quarter Results 10427 18Flextronics Announces Third Quarter Results 10427 19
...Calif., June 05, 2007 /PRNewswire/ -- MAP,Pharmace... Phase 2,data from its MAP0004 migraine therapy cl...e Society Meeting at the Hyatt Regency,Chicago in ...was,accepted as a late-breaker, is entitled Rapid ...led Dihydroergotamine Mesylate,via a Novel Inhaler...
...une 05, 2007 /PRNewswire/ -- , Professor Home said...ppointing and,misleading in that they disregarded ...nt to patients and physicians. Most,significantly ...e,of any increase in cardiovascular death or death...T: Professor Philip Home, (44) 778-525-1736 , Ter...
Other Medicine Technology:MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the,American Headache Society Meeting 2
...e BP monitor is designed to automatically measure ...BP along with heart rate. It's a Blood Pressure mo...ergometer and pharmacological stress test environm...ronments., ,Tango excels where other BP monit...
BD Visiswab Cotton Swab
...l, Philips Zymed 1810 Series offers retrospective ... the operator the flexibility to adjust the algori...application beyond the basic 1810 and you have eve...matic style that best meets the challenges of each...
...s STG for PC captures, displays, replays and analy...be effective in evaluating heart illnesses, pneumo...ase.,It provides objective evidence as a complem...time-expanded waveform displays, Phonocardiogra...
Medicine Products: